Improving Immunotherapy for Melanoma with a New Vaccine Delivery Method
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11119009
This project is developing a new type of vaccine to make existing melanoma immunotherapies work better for more patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11119009 on ClinicalTrials.gov |
What this research studies
Melanoma is a serious skin cancer, and while current immunotherapies help some patients, many do not respond. This work aims to create a more effective vaccine that can be combined with existing treatments. The vaccine is designed to deliver specific tumor signals and immune-boosting agents directly to the lymph nodes, which are key sites for immune responses. By improving how these vaccine components reach the immune system, we hope to strengthen the body's ability to fight melanoma.
Who could benefit from this research
Good fit: This research is focused on improving treatments for patients with advanced melanoma.
Not a fit: Patients without melanoma or those already responding well to current therapies may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this approach could lead to more effective treatments for advanced melanoma, especially for patients who do not currently respond to immunotherapy.
How similar studies have performed: While peptide vaccines have been tested, their effectiveness has been limited, making this targeted delivery strategy a novel approach to overcome previous challenges.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHU, GUIZHI — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: ZHU, GUIZHI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.